Efficacy of etanercept in psoriatic patients previously treated with infliximab
Related Experiment Video
Updated: Jul 7, 2026
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
Gerard Pitarch1, José Luís Sánchez-Carazo, Laura Mahiques
1Servicio de Dermatología, Hospital General Universitario, Valencia, Spain. gerardpitarch@hotmail.com
Background:
There are few data to enable us to ascertain whether switching to another systemic agent is useful in patients with psoriasis who have not responded favorably to a first systemic treatment.
Objective:
To evaluate the efficacy and safety of etanercept in patients with moderate-to-severe plaque psoriasis previously treated with infliximab.
Methods:
We analyzed data from patients with moderate-to-severe psoriasis and a poor primary or secondary response to infliximab, and who were later treated with etanercept.
Results:
Data were collected from 8 patients who were first treated with infliximab. At 54 weeks of therapy, 25% had a psoriasis area and severity index (PASI) of 75. At 24 weeks of therapy with etanercept, 75% had a PASI of 75. Consecutive administration of both therapies did not increase the number of adverse events.
Limitations:
The data should be regarded with caution due to the scant number of patients.
Conclusions:
Switching from infliximab to etanercept can be useful and safe in nonresponders.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
01:22Dose-Response Relationship: Potency and Efficacy
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...